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Cerebrospinal ﬂuidChildren and adults with malignant diseases have a high risk of prevalence of the tumor in the central
nervous system (CNS). As prophylaxis treatment methotrexate is often given. In order to monitor meth-
otrexate exposure in the CNS, cerebrospinal ﬂuid (CSF) concentrations are often measured. However, the
question is in how far we can rely on CSF concentrations of methotrexate as appropriate surrogate for
brain target site concentrations, especially under disease conditions.
In this study, we have investigated the spatial distribution of unbound methotrexate in healthy rat
brain by parallel microdialysis, with or without inhibition of Mrp/Oat/Oatp-mediated active transport
processes by a co-administration of probenecid. Speciﬁcally, we have focused on the relationship
between brain extracellular ﬂuid (brainECF) and CSF concentrations. The data were used to develop a sys-
tems-based pharmacokinetic (SBPK) brain distribution model for methotrexate. This model was subse-
quently applied on literature data on methotrexate brain distribution in other healthy and diseased
rats (brainECF), healthy dogs (CSF) and diseased children (CSF) and adults (brainECF and CSF).
Important differences between brainECF and CSF kinetics were found, but we have found that inhibition
of Mrp/Oat/Oatp-mediated active transport processes does not signiﬁcantly inﬂuence the relationship
between brainECF and CSF ﬂuid methotrexate concentrations.
It is concluded that in parallel obtained data on unbound brainECF, CSF and plasma concentrations,
under dynamic conditions, combined with advanced mathematical modeling is a most valid approach
to develop SBPK models that allow for revealing the mechanisms underlying the relationship between
brainECF and CSF concentrations in health and disease.
 2014 The Authors. Published by Elsevier B.V.Open access under CC BY-NC-ND license. 1. Introduction
Methotrexate was introduced into the treatment of malignant
diseases more than 50 years ago (Hertz et al., 1956). Today, many
treatment protocols for malignant diseases, like acute lymphoblas-
tic leukemia, have established the combination of high-dose meth-
otrexate (to decrease the fraction of plasma protein binding),
combined with leucovorin rescue (Djerassi et al., 1967; Moe and
Holen, 2000). Before the use of central nervous system (CNS) pro-
phylaxis, the CNS was the most frequently reported site of initial
recurrence in children with acute lymphoblastic leukemia,
accounting for up to 75% of cases (Bleyer and Poplack, 1985; Evanset al., 1970). However, in the treatment of acute lymphoblastic leu-
kemia, prophylactic CNS therapy effectively reduced the rate of
CNS relapses (Balis and Poplack, 1989; Blaney and Poplack, 1996;
Clarke et al., 2003; Smith et al., 1996). Still, CNS recurrence remains
a major limitation to achieving complete cure, accounting for 30–
40% of recurrences in some pediatric clinical trials (Hutchinson
et al., 2003; Lange et al., 2002).
The use of cranial irradiation for CNS prophylaxis is effective
but associated with severe late effects (Clarke et al., 2003; Ochs
and Mulhern, 1994). Today, the combination of high-dose metho-
trexate and intrathecal methotrexate, employed to reduce such
treatment-related late effects, has successfully replaced cranial
irradiation as CNS prophylaxis in most patients (about 80–90%)
of acute lymphoblastic leukemia (Cáp et al., 1998; Pui et al.,
2009). However, the intrathecal methotrexate procedure is suscep-
tible to complications and stressful for the patient, especially for
children (Keidan et al., 2005). Therefore, it has been suggested that
the use of high-dose intravenous methotrexate alone could be suf-
ﬁcient for CNS prophylaxis (Niemann et al., 2010).
Nomenclature
Ai amount of methotrexate in compartment i (ng)
Ci concentration of methotrexate in compartment i (ng/
ml)
k rate constant (min1)
Q ﬂow rate (ml/min)
CL clearance (ml/min)
V volume (ml)
Subscripts
PL plasma
PL,u unbound methotrexate in plasma
PER,rapid rapidly equilibrating peripheral compartment
PER,slow slowly equilibrating peripheral compartment
ECF brainECF
CSF CSF
LV lateral ventricle
TFV third and fourth ventricle
CM cisterna magna
SAS subarachnoid space
12 J. Westerhout et al. / European Journal of Pharmaceutical Sciences 57 (2014) 11–24On the basis of in vitro testing, a methotrexate concentration of
0.45 lg/ml at the target site is commonly acknowledged as effec-
tive in killing tumor cells (Hryniuk and Bertino, 1969). With the
CNS being the target site for CNS prophylaxis, it is the aim to have
the appropriate methotrexate concentration in the brain extracel-
lular ﬂuid (brainECF). However, as blood–brain barrier (BBB) trans-
port is highly restricted for methotrexate, plasma concentrations
need to be far higher than the 0.45 lg/ml to be able to reach appro-
priate concentrations in the CNS. As a result, the exposure of the
rest of the body to cytotoxic concentrations is quite substantial
(Chabner and Young, 1973; Ferreri et al., 2004).
The information on the relationship between plasma and CNS
methotrexate concentrations appears to be inconsistent, with lin-
ear relationships reported by Borsi and Moe (1987), Jönsson et al.
(2007), Millot et al. (1994), whereas Milano et al. (1990), Thyss
et al. (1987) and Vassal et al. (1990) reported non-linear relation-
ships. Therefore, CNS concentrations are often monitored for
appropriate dose selection (Niemann et al., 2010). To that end,
CSF concentrations are used, since brainECF concentrations are
not readily measurable in humans. CSF concentrations are consid-
ered to be the best available surrogate (Fridén et al., 2009; Kalvass
and Maurer, 2002; Maurer et al., 2005; Liu et al., 2006, 2009), with
the assumption that CSF concentrations readily equilibrate with
brainECF concentrations due to the lack of a physical barrier be-
tween these sites (Lee et al., 2001). However, due to qualitative
and quantitative differences between processes that govern the
pharmacokinetics (PK) of drugs in the brainECF vs. CSF, a generally
applicable relationship between the PK at these two sites does not
exist and needs evaluation (De Lange and Danhof, 2002; Lin, 2008;
Shen et al., 2004; Westerhout et al., 2011).
We have previously shown that even for acetaminophen, inves-
tigated as model compound for passive transport into, within and
out of the brain, differences exist between CSF and brainECF kinetics
(Westerhout et al., 2012). Furthermore, we have also shown that
for quinidine, a model compound for P-gp mediated transport, dif-
ferences exist between CSF and brainECF kinetics, which are very
much dependent on P-gp functionality (Westerhout et al., 2013).
With methotrexate being a substrate for a wide variety of trans-
porters that are all located at the BBB and BCSFB (including the re-
duced folate carrier 1 (RFC1) (Hinken et al., 2011), breast cancer
resistance protein (BCRP) (Breedveld et al., 2007), multidrug resis-
tance-associated proteins (MRP) 2, 3 and 4 (Vlaming et al., 2011),
organic anion transporter (OAT) 1 and 3 (Takeda et al., 2002),
and organic anion-transporting polypeptides (OATP) A (Badagnani
et al., 2006) and OATP B (van de Steeg et al., 2009)), this could have
major implications for the predictability of brainECF methotrexate
concentrations on the basis of CSF concentrations. Consequently,
to be able to know whether methotrexate brainECF concentrations
can be adequately predicted by CSF concentrations, one should ﬁrst
understand the mechanisms that determine the relationship be-
tween CSF concentrations and brainECF concentrations.In this study we have used the parallel intracerebral probe
microdialysis approach (striatum, lateral ventricle, and cisterna
magna (Westerhout et al., 2012) in conjunction with parallel blood
sampling, for continuous measurement and direct comparison of
changes in concentrations in plasma, brainECF and CSF kinetics of
methotrexate. To investigate the speciﬁc contribution of the vari-
ous transporters, probenecid is co-administered as inhibitor of
MRPs (Bakos et al., 2000), OATs (Sugiyama et al., 2001) and OATPs
(Kis et al., 2013). Advanced mathematical modeling is applied to
extrapolate the data to other conditions, and other species, includ-
ing human.
2. Materials and methods
2.1. Chemicals
Methotrexate solution for injection (Emthexate PF) and isoﬂu-
rane were obtained from Pharmachemie B.V. (Haarlem, the Nether-
lands). Methotrexate (powder), aminopterin and ammonium
formate were from Sigma–Aldrich (Zwijndrecht, the Netherlands).
Probenecid, 5% glucose and saline were obtained from the Leiden
University Medical Centre pharmacy (Leiden, the Netherlands).
Acetonitrile (HPLC-S grade), methanol (ULC-grade) and formic acid
(ULC grade) were from Biosolve (Valkenswaard, the Netherlands).
Ammonium hydroxide (25%), magnesium chloride, sodium acetate,
sodium chloride, calcium chloride and perchloric acid, were ob-
tained from Baker (Deventer, the Netherlands). Potassium chloride
was from Merck (Darmstadt, Germany). All other chemicals were
of analytical grade. Microdialysis perfusion ﬂuid was prepared as
previously described (Westerhout et al., 2012), containing
140.3 mM sodium, 2.7 mM potassium, 1.2 mM calcium, 1.0 mM
magnesium and 147.7 mM chloride.
2.2. Animals
The study protocol was approved by the Animal Ethics Commit-
tee of Leiden University (UDEC nr. 10094). All animal procedures
were performed in accordance with Dutch laws on animal experi-
mentation. A total of 40 male Wistar WU rats (225–275 g, Charles
River, Maastricht, the Netherlands) were randomly divided into
two groups; the ﬁrst group (n = 8) was used for the determination
of the in vivo microdialysis probe recovery; the second group
(n = 32) was used for brain disposition experiments. This second
group was further divided into four subgroups, designated for 40
or 80 mg/kg methotrexate without or with co-administration of
probenecid (denoted as 40, 40+, 80 and 80+, respectively).
After arrival, all animals were housed in groups for 5–7 days
(Animal Facilities, Gorlaeus Laboratories, Leiden, the Netherlands),
under standard environmental conditions (ambient temperature
21 C; humidity 60%; 12/12 h light/dark cycle, background noise,
daily handling), with ad libitum access to food (Laboratory chow,
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tween surgery and experiments, the animals were kept individu-
ally in Makrolon type three cages for 7 days to recover from the
surgical procedures.2.3. Surgery
All surgical procedures were performed as described by West-
erhout et al. (2012). In short, cannulas were implanted in the left
femoral artery and vein for blood sampling and drug administra-
tion, respectively. Both cannulas were subcutaneously led to the
back of the head and ﬁxated in the neck with a rubber ring. Subse-
quently, the animals were chronically instrumented with two
CMA/12 microdialysis guides (CMA/Microdialysis AB, Stockholm,
Sweden) in different combinations of striatum (ST), for sampling
in brainECF, and lateral ventricle (LV) and/or cisterna magna (CM)
for sampling in CSF (ST + LV, ST + CM or LV + CM). For ST, the posi-
tion of the microdialysis guide is: 1.0 mm anterior, 3.0 mm lateral,
3.4 mm ventral, relative to bregma. For LV, the position of the
microdialysis guide is: 0.9 mm posterior, 1.6 mm lateral, 2.9 mm
ventral, relative to the bregma. For CM, the position of the micro-
dialysis guide is: 1.93 mm posterior, 3.15 mm lateral, 8.1 mm ven-
tral, at an angle of 25 from the dorsoventral axis (towards
anterior) and 18 lateral from the anteroposterior axis relative to
lambda. The microdialysis guides were secured to the skull with
3 anchor screws and dental cement.
After the surgery the animals received 0.03 ml Temgesic  intra-
muscularly (Schering-Plough, Amstelveen, The Netherlands) and
0.3 ml Ampicillan (Alfasan B.V., Woerden, The Netherlands) sub-
cutaneously. One day prior to the experiment, the microdialysis
dummies were replaced by the microdialysis probes (CMA/12 Elite,
Polyarylethersulfone, molecular weight cut-off 20 kDa, CMA/
Microdialysis AB, Stockholm, Sweden, with a semi-permeable
membrane length of 4 mm for ST, and 1 mm for LV and CM).2.4. Experimental set-up
All experiments were performed as described by Westerhout
et al. (2012), with some modiﬁcations. In short, the in vivo micro-
dialysis probe recovery of methotrexate was determined on the ba-
sis of reverse dialysis (Ståhle et al., 1991). The microdialysis probes
in striatum, lateral ventricle and cisterna magna were perfused
with different concentrations of methotrexate (50, 200 and
1000 ng/ml) in perfusion ﬂuid. To evaluate the potential effect of
co-administration of probenecid on the in vivo recovery of metho-
trexate, several animals received an intravenous infusion of
150 mg/kg probenecid in 5% NaHCO3 in saline (150 ll/min/kg for
a period of 10 min) with an automated pump (Pump 22 Multiple
Syringe Pump, Harvard Apparatus, Holliston, USA) 30 min prior
to the start of the reverse dialysis experiment. Control animals re-
ceived an intravenous infusion of vehicle (150 ll/min/kg, for a per-
iod of 10 min).
The in vivo recovery is deﬁned as the ratio of the concentration
difference between the dialysate (Cdial) and perfusion ﬂuid (Cin)
over the concentration in the perfusion ﬂuid (Eq. (1)) (Scheller
and Kolb, 1991).
In vivo recovery ¼ Cin  Cdial
Cin
ð1Þ
For the brain disposition experiments, the rats ﬁrst received an
intravenous infusion of 150 mg/kg probenecid in 5% NaHCO3 in sal-
ine or vehicle (150 ll/min/kg, for a period of 10 min) 30 min prior
to the administration of 40 or 80 mg/kg methotrexate in saline
(200 ll/min/kg for a period of 10 min). The start and duration of
the infusion was corrected for internal volume of the tubing so thatinfusion started at t = 0 min. 10 min interval samples were col-
lected between t = 1 h and t = 5 h. After weighing the microdialy-
sis vials they were stored at 80 C before analysis.
For the determination of methotrexate plasma concentrations,
blood samples of 100 ll were taken, in parallel to the microdialy-
sate samples, from the arterial cannula at t = 5 (blank), 2, 7, 9,
10, 12, 17, 30, 90, 180, and 300 min. All blood samples were tem-
porarily stored in heparin (10 IU) coated Eppendorf cups before
being centrifuged for 15 min at 5000 rpm. The plasma was then
pipetted into clean Eppendorf cups and stored at 20 C before
analysis.
At the end of the experiments the animals were sacriﬁced with
an overdose of Nembutal (Ceva Sante Animale, Libourne, France).
2.5. Plasma protein binding
For the determination of plasma protein binding of methotrex-
ate, plasma samples of different time points were pooled (combin-
ing t = 2 and 7; t = 9 and 10; t = 12 and 17; t = 30 and 90; t = 180
and 300) to span the entire concentration range. Plasma protein
binding was determined with Centrifree ultraﬁltration devices
(Millipore BV, Etten-Leur, the Netherlands). All procedures were
performed according to the user’s manual. The ultraﬁltrate was di-
luted 10 times with saline before the analysis.
2.6. Concentration analysis
Methotrexate concentrations in plasma, plasma ultraﬁltrate and
microdialysate were quantiﬁed using an on-line solid phase
extraction (SPE) with liquid chromatography–tandem mass spec-
trometry (LC/MS/MS) system, based on previous work by Rule
et al. (2001) and Guo et al. (2007).
2.6.1. Sample preparation
To 20 ll of plasma and plasma ultraﬁltrate, 20 ll internal stan-
dard (10 lg/ml aminopterin) was added. After mixing with 40 ll of
6% perchloric acid and centrifugation for 10 min at 10,000g, 60 ll
of the supernatant was thoroughly mixed with 40 ll of 1 M sodium
acetate. 20 ll was then injected on the SPE column.
To 15 ll of the microdialysate samples, 15 ll of the internal
standard (250 ng/ml aminopterin) was added. After mixing, 10 ll
was injected on the SPE column.
2.6.2. Solid phase extraction
HySphere™ SPE cartridges and a cartridge holder from Spark
(Emmen, the Netherlands) were used in combination with the di-
vert/inject valve of the mass spectrometer to prevent salt entering
the mass spectrometer. After ﬂushing under acidic conditions, the
SPE was switched onto the LC system and methotrexate and its
internal standard were eluted from the SPE to the LC column. For
plasma precipitates, C-8 HD SE cartridges were used, while for
microdialysate samples C-18 cartridges were used. After injection
of the sample on the SPE column, salts from either precipitated
plasma or microdialysate samples were ﬂushed to waste before
analysis on the HPLC column. A quaternary gradient HPLC pump
(P580) from Dionex (Breda, the Netherlands) was used for the
on-line SPE method, while a Surveyor pump (Thermo Scientiﬁc,
Breda, the Netherlands) served as delivery unit for the HPLC
column.
2.6.3. Chromatographic Conditions
The VisionHT C-18B column (Grace Alltech, Breda, the Nether-
lands) was thermostatted at 37 C. The mobile phase consisted of
21% methanol and 79% lab water, derived from a PURELAB Ultra
system (Veolia Water Solutions, Ede, the Netherlands), containing
0.2% formic acid and 1 mM ammonium formate. After isocratic
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umn was ﬂushed with 90% methanol and 10% lab water containing
0.2% formic acid and 1 mM ammonium formate 7–9.5 min after
injection.
2.6.4. Mass spectrometry
Sample analysis was performed on a Finnigan TSQ Quantum Ul-
tra Mass Spectrometer System (Thermo Scientiﬁc, Breda, the Neth-
erlands). Electrospray ionization was used in the positive mode at
3500 V. Methotrexate was quantiﬁed using selected reaction moni-
toring (SRM) with the transition 455–308 (m/z). The internal stan-
dard, aminopterin, had a SRM transition of 441–294 (m/z). The
collision energy used was 18 V, scan width was set at 0.7 m/z and
both Q1 and Q3 were set to 0.70 full width at half maximum
(FWHM). The scan timewas 0.11 s. Argon served as the collision gas.
2.7. Pharmacokinetic data analysis
All plasma concentrations were converted to unbound plasma
concentrations, by correction for plasma protein binding. All
microdialysate concentrations from striatum, lateral ventricle
and cisterna magna were converted into brainECF concentrations
(CECF) or CSF concentrations (CCSF) by division of the dialysate con-
centrations by the average in vivo recovery as determined for each
microdialysis probe location (Eq. (2)).
CECF or CCSF ¼ Cdialinvivo recovery ð2Þ
Areas under the curve from t = 0 to t = 300 min (AUC0–300) were cal-
culated by the trapezoidal rule and tested for differences by single
factor ANOVA. The population PK models were developed and ﬁtted
to the data by means of non-linear mixed-effects modeling using
the NONMEM software package (version 6.2, Icon Development
Solutions, Ellicott City, Maryland, USA) and analyzed using the
statistical software package S-Plus for Windows (version 6.2 Pro-
fessional, Insightful Corp., Seattle, USA).
The pharmacokinetic model for methotrexate plasma and brain
concentrations was based on the systems-based PK (SBPK)
approach we have previously applied to investigate the exchange
between brainECF and CSF of acetaminophen (Westerhout et al.,
2012) and quinidine (Westerhout et al., 2013). For this approach,
the volumes of the different brain compartments were ﬁxed to
their physiological volumes. The rat brain intracellular space and
brainECF volume were assumed to be 1.44 ml (Thorne et al., 2004)
and 290 ll (Cserr et al., 1981), respectively. With a total CSF vol-
ume of 300 ll in the rat (Bass and Lundborg, 1973), the volumes
of the lateral ventricles, third and fourth ventricles, cisterna magna
and subarachnoid space were assumed to be 50 ll (Condon et al.,
1986; Kohn et al., 1991), 50 ll (Levinger, 1971), 17 ll (Adam and
Greenberg, 1978; Robertson, 1949) and 180 ll (Bass and Lundborg,
1973; Levinger, 1971), respectively. The intra-brain distribution
was restricted by the physiological ﬂow paths of brainECF, in which
brainECF ﬂows towards the CSF compartments at a rate of 0.2 ll/
min (Abbott, 2004; Cserr et al., 1981), and CSF ﬂows from lateral
ventricle, through the third and fourth ventricle, to the cisterna
magna and subsequently to the subarachnoid space (cranial and
spinal) and back into blood at a rate of 2.2 ll/min (Cserr, 1965).
Structural model selections for both the blood and brain PK
model were based on the likelihood ratio test (p < 0.01), diagnostic
plots (observed concentrations vs. individual and population pre-
dicted concentrations, weighted residuals vs. predicted time and
concentrations), parameter correlations and precision in parameter
estimates. The inter-animal variability in pharmacokinetic param-
eters was assumed to be log normally distributed. The residual
error, which accounts for unexplained variability (e.g. measure-ment and experimental error and model-misspeciﬁcation), was
best described with a proportional error model.
The validity of the pharmacokinetic models was investigated by
means of a visual predictive check. (Cox et al., 1999; Duffull and
Aarons, 2000; Yano et al., 2001) Using the ﬁnal PK parameter esti-
mates, 1000 curves were simulated. Subsequently, the median and
the 5th and 95th percentile of the predicted concentrations were
calculated, which represent the 90% prediction interval. These
were then compared with the observations.
In order to test the ruggedness of the model and estimate the
precision of the parameters n = 100 non-parametric (case resam-
pling) bootstraps were performed. To create the bootstrapped
datasets, speciﬁc rat data (plasma and microdialysate concentra-
tions) were removed randomly from the datasets and replaced
with randomly selected rat data from the complete original data-
set. Each of these permutations of the original dataset was ﬁtted
with the ﬁnal model determined based on the original dataset. This
results in a series of model ﬁts, each with its own set of parame-
ters. These results were displayed graphically and the descriptive
statistics of the parameters were compared to parameter estimates
of the ﬁnal model. Only bootstrap runs that successfully minimized
were used in this analysis.2.8. Systems-based scaling
The SBPK model was ﬁrst used to predict the methotrexate plas-
ma and brainECF concentration–time proﬁles of brain tumor-bear-
ing rats (De Lange et al., 1995), to investigate the impact of
disease-status on the kinetics of methotrexate. Next, the parame-
ters of the rat SBPK were extrapolated to healthy dogs (Neuwelt
et al., 1985), to investigate the validity of using this approach for
interspecies scaling. To do so, the elimination clearance was ﬁrst
divided into renal clearance and hepatic clearance, with renal
clearance assumed to be identical to the glomerular ﬁltration rate
(Brcakova et al., 2009) and the remaining clearance assigned to
hepatic clearance. The hepatic clearance was then scaled to the
number of hepatocytes in rat or dog liver. Next, the transfer clear-
ances between plasma and the different peripheral and brain com-
partments were scaled based on
CLPL-PER ¼ A PER ðVPERÞ0:67 ð3ÞCLPL-BR ¼ A BR ðVBRÞ0:67 ð4Þ
In which APER and ABR are scaling coefﬁcients for periphery and
brain, respectively, and both are estimated on the basis of the rat
data (Hosseini-Yeganeh and McLachlan, 2002). VPER represents the
physiological volume of the (lumped) peripheral tissues for rapid
(including muscle, kidney, intestine and liver) and slow equilibra-
tion (including adipose, skin, heart, bone and remaining tissue).
VBR represents the physiological volume of the different brain com-
partments. The scaling factor of 0.67 is based on the permeability
surface area of the different brain compartments, which is related
to the tissue weight (Kawai et al., 1994). The physiological parame-
ters of the rat SBPK model were changed accordingly.
Finally, the parameters of the rat SBPK were extrapolated to the
human setting, which included adults and children with different
disease-states, using the same approach as applied for extrapola-
tion to dogs.3. Results
All results are presented as average values ± standard error of
the mean, unless stated otherwise.
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The average unbound plasma (plasmau), brainECF, lateral ventri-
cle (CSFLV) and cisterna magna (CSFCM) methotrexate concentra-
tions following the 40 and 80 mg/kg dose with or without
co-administration of probenecid are shown in Fig. 1. Plasma pro-
tein binding of methotrexate was linear at an extent of
55.2 ± 7.7%. It was not affected by co-administration of probenecid.
The co-administration of probenecid slightly altered the distribu-
tion phase for both the 40 and 80 mg/kg dose of methotrexate.
Data obtained by microdialysis from the brainECF, CSFLV and CSFCM
were corrected for in vivo recovery. The average in vivo recoveries
for the methotrexate concentrations in striatum, lateral ventricle
and cisterna magna probes were inﬂuenced by co-administration
of probenecid and were determined to be 22.1 ± 2.0%, 28.1 ± 2.9%
and 35.9 ± 2.5%, for the control group and 7.1 ± 0.9%, 16.9 ± 1.7%
and 21.6 ± 5.6% for the probenecid group, respectively.
It can be seen that a higher dose of methotrexate leads to higher
methotrexate concentrations in all brain compartments, but not to
the same extent. Probenecid increased methotrexate concentra-
tions signiﬁcantly (p < 0.01) in all brain compartments. The effect
of probenecid was dependent on the methotrexate dose; at the
higher dose of methotrexate, the increase in methotrexate concen-
trations was more profound for brainECF and CSFLV, as can be seen
by the average unbound brain (brainu)-to-plasmau AUC0–300 ratios
(Table 1). However, the dose-dependency was not signiﬁcant. The
relationship between brainECF-to-CSF concentration ratios was not
signiﬁcantly affected by probenecid co-administration, and was on
average 7.7 ± 3.7 (Table 2).
3.2. Systems-based modeling approach
As it was our goal to investigate the relationship between
brainECF and CSF pharmacokinetics, we have applied a SBPKFig. 1. Average (geometric mean ± SEM) unbound methotrexate concentration–time pro
co-administration of probenecid (150 mg/kg). (A) 40 mg/kg methotrexate dose: for plasm
CSFCM (n = 3 () and 4 (+)). (B) 80 mg/kg methotrexate dose. Plasma (n = 7 () and 7 (+))
(+)).
Table 1
Brainu-to-plasmau AUC0–360 ratios for brain ECF, CSFLV and CSFCM for the 40 mg/kg and 80
Brainu-to-plasmau AUC0–300 ratios 40
BrainECF 2.5 ± 1.7%
CSFLV 0.6 ± 0.1%
CSFCM 0.4 ± 0.1%
* Signiﬁcantly (p < 0.05) different from the group without co-administration of probene
 Signiﬁcantly (p < 0.05) different from the CSF-to-plasmau AUC0–300 ratios.modeling approach like we did previously for analysis of regional
brain distribution of acetaminophen (Westerhout et al., 2012)
and quinidine (Westerhout et al., 2013). To adequately describe
CSF physiology, we have used four CSF compartments that repre-
sent the CSFLV, the combined third and fourth ventricle (CSFTFV),
the CSFCM and the subarachnoid space (CSFSAS). Since we have no
measurements of the concentrations in the third and fourth ventri-
cle, the transfer clearance between plasma and third and fourth
ventricle was assumed to be equal to the transfer clearance
between plasma and lateral ventricle.
3.2.1. Distinction between passive and active transport clearances
The active component of the different transfer clearances be-
tween plasma and the brain compartments was determined by
comparing the parameter estimations for the rats that did to those
rats that did not receive the co-administration of probenecid. Even
though methotrexate is transported by a wide variety of transport-
ers, the co-administration of the Mrp-, Oat- and Oatp-inhibitor
probenecid allowed us to investigate the impact of combined
Mrp-, Oat- and Oatp-mediated transport. The active component
of the transfer clearances between plasma and the different brain
compartments was incorporated into the model as previously de-
scribed by Syvänen et al. (2006):
CLPL-BR ¼ CLPL-BR;p  CLPL-BR;a ð5Þ
CLBR-PL ¼ CLBR-PL;p þ CLBR-PL;a ð6Þ
where the subscript ‘p’ denotes passive transport and ‘a’ denotes ac-
tive transport. For the animals that received a co-administration of
probenecid, both CLPL-BR,a and CLBR-PL,a were considered to be 0.
3.2.2. Modeling Mrp-, Oat- and Oatp-mediated transport
Both Mrps, Oats, as well as Oatps have been well described as
efﬂux transporters at the BBB and BCSFB (Graff and Pollack,ﬁles following intravenous administration of methotrexate, with (+) or without ()
a (n = 7 () and 6 (+)), brainECF (n = 5 () and 4 (+)), CSFLV (n = 4 () and 3 (+)) and
, brainECF (n = 4 () and 5 (+)), CSFLV (n = 5 () and 4 (+)) and CSFCM (n = 6 () and 3
mg/kg dose without () and with (+) co-administration of probenecid.
40+ 80 80+
5.9 ± 1.1%*  2.5 ± 0.3% 9.8 ± 3.3%* 
1.6 ± 1.0% 0.5 ± 0.3% 3.5 ± 0.4%*
0.8 ± 0.1% 0.7 ± 0.4% 0.9 ± 0.5%
cid.
Table 2
BrainECF-to-CSF concentration ratios for the 40 mg/kg and 80 mg/kg dose without () and with (+) co-administration of probenecid. (No signiﬁcant differences were found.)
BrainECF-to-CSF concentration ratios 40 40+ 80 80+
BrainECF-to-CSFLV 9.6 ± 5.0 6.0 ± 2.9 11.6 ± 7.0 5.2 ± 2.4
BrainECF-to-CSFCM 11.5 ± 5.5 8.3 ± 1.6 6.0 ± 2.3 12.7 ± 3.0
BrainECF-to-CSFaverage 10.2 ± 4.8 6.8 ± 2.1 7.6 ± 3.3 7.2 ± 2.7
Fig. 2. Diagram of the SBPK model that was used to describe the intra-brain
distribution of methotrexate in the rat. CLE is the elimination clearance from
plasma. Further, for transfer clearances between compartments (CLfrom comp-to comp),
denotations of the compartments are: PL = plasma; rapidly equilibrating periph-
ery = PER,rapid; slowly equilibrating periphery = PER,slow; ECF = brainECF;
DBR = braindeep; LV = lateral ventricle; TFV = third and fourth ventricle; CM = cis-
terna magna and SAS = subarachnoid space. QECF is the ﬂow rate of brainECF, QCSF is
the ﬂow rate of CSF. The subscript ‘p’ denotes passive transport and ‘a’ denotes
active transport. V = physiological volume, not shown in the diagram.
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can exert their effect could be by reduced the transfer clearance
from plasma to the brain compartments (i.e. inﬂux hindrance;
Eq. (5)) or by increased the transfer clearance from the brain com-
partments to plasma (i.e. efﬂux enhancement; Eq. (6)) or both. The
data were best described by the model with Mrp, Oat and Oatp
functioning solely by inﬂux hindrance. Interestingly, the observa-
tion that in vivo probe recovery of methotrexate was affected by
probenecid indicates that methotrexate is transported by Mrps,
Oats and Oatps via the efﬂux enhancement mechanism (Syvänen
et al., 2006). However, estimation of the active components when
Mrp, Oat and Oatp were considered to function by efﬂux enhance-
ment resulted in too large coefﬁcients of variation. Also, the esti-
mation of the active component in the transfer between plasma
and cisterna magna resulted in too large coefﬁcients of variation
and was therefore assumed to be absent.
3.2.3. Modeling methotrexate concentration-dependent Mrp-, Oat- or
Oatp-mediated transport
Since Mrp-, Oat- or Oatp-mediated transport is an active (satu-
rable) process we have also tried to identify the maximal transport
rate (Tm) and the blood- or brain concentration for half-maximal
transport (Km) as follows:
CLPL-BR;a ¼ Tm;PL-BRKm;PL-BR þ CPL;u ð7Þ
CLBR-PL;a ¼ Tm;BR-PLKm;BR-PL þ CBR ð8Þ
where CPL,u is the unbound plasma concentration and CBR is the con-
centration in one of the brain compartments. The parameter esti-
mations of Tm and Km resulted in high values for both Tm and Km
(results not shown), indicating that the plasma and brain concen-
trations in this study are not sufﬁciently high for saturating Mrp-,
Oat- or Oatp-mediated transport. The parameter estimations of Tm
and Km also resulted in too large coefﬁcients of variation. Thus,
our data were insufﬁcient to determine the values of these param-
eters. Therefore, Mrp-, Oat- or Oatp-mediated transport had to be
incorporated by means of a single active transport clearance value,
rather than by Tm and Km.
3.2.4. Final SBPK model
The ﬁnal SBPK model is shown in Fig. 2. The differential equa-
tions of this model can be found in the Appendix A. The ﬁnal esti-
mation of the PK parameters is summarized in Table 3.
Interestingly, no active component on the elimination clearance
could be identiﬁed, whereas this was the case for the compartmen-
tal pharmacokinetic analysis of the plasma concentrations only
(results not shown).
According to Brcakova et al. (2009) the rate of renal clearance of
unbound methotrexate in rats equals the rate of renal creatinine
clearance, which is a measure of the glomerular ﬁltration rate
(GFR; 1.4 ml/min in the rat (Atherton, 1983)). Consequently, the
remaining methotrexate clearance is hepatically. Based on our re-
sults, the rate of hepatic clearance is therefore 7.35 ml/min in the
rat. With a total hepatic blood ﬂow of approximately 11.8 ml/
min (Davies and Morris, 1993), this results in a hepatic extraction
ratio of 62%, which is comparable to the 53% reported previously
by Kates and Tozer (1976).The visual predictive check of the ﬁnal model is given in Fig. 3. It
can be seen that the ﬁnal model describes the data very well within
the 95% prediction interval, and also can cope with the large inter-
individual variation in brain concentrations.
3.3. Systems-based scaling
The physiological and PK parameters of the rat, dog and human
children and adults that were used for the extrapolation are given
in Table 3.
3.4. Extrapolation to other healthy and to diseased rats
We have applied the ﬁnal SBPK model to investigate the impact
of disease-status on the PK of methotrexate in plasmau and
brainECF of brain tumor-bearing rats, compared to healthy control
Table 3
Final estimation of the rat PK parameters of methotrexate for the SBPK model (±standard error) and predicted dog and human parameters.
Parameter Rat value Dog value (20–25 kg) Human child value (9 year old, 30 kg
bodyweight)
Human adult value
fu,p 44.8 ± 7.7% 60% (Henderson et al., 1965) 67.7% (Skibin´ska et al., 1990) 67.7% (Skibin´ska et al., 1990)
CLE,p 8.75 ± 0.85 ml/min 88.2 ml/min (based on 1.1 * GFR
(Henderson et al., 1965))
163.2 ml/min (based on 2 * GFR
(Hendel and Brodthagen, 1984))
250 ml/min (based on 2 * GFR
(Hendel and Brodthagen, 1984))
GFR 1.4 ml/min (Atherton, 1983) 80.2 ml/min (Von Hendy-Willson
and Pressler, 2011)
Age dependent (81.6 ml/min for 9 year
old) (Schwartz et al., 1976)
125 ml/min (Davies and Morris,
1993)
CLE,a N.A. N.A. N.A. N.A.
CLPL-PER,rapid 31.5 ± 4.9 ml/min 748.2 ml/min 606.0 ml/min 1047.2 ml/min
CLPER,rapid-PL 2.45 ± 0.34 ml/min 582.0 ml/min 471.3 ml/min 814.5 ml/min
CLPL-PER,slow 2.94 ± 0.91 ml/min 38.1 ml/min 72.6 ml/min 146.5 ml/min
CLPER,slow-PL 0.25 ± 0.04 ml/min 32.4 ml/min 61.8 ml/min 124.5 ml/min
CLPL-ECF,p 1.81 ± 0.48 ll/min 29.8 ll/min 176.6 ll/min 180.9 ll/min
CLPL-ECF,a 1.29 ± 0.41 ll/min 21.3 ll/min 125.8 ll/min 128.9 ll/min
CLECF-PL 17.0 ± 4.4 ll/min 280.2 ll/min 1658.3 ll/min 1699.2 ll/min
CLPL-LV,p 0.12 ± 0.04 ll/min 2.18 ll/min 5.55 ll/min 7.19 ll/min
CLPL-LV,a 0.09 ± 0.03 ll/min 1.64 ll/min 4.17 ll/min 5.39 ll/min
CLLV-PL 3.69 ± 1.57 ll/min 67.2 ll/min 170.8 ll/min 221.1 ll/min
CLPL-TFV,p 0.12 ± 0.04 ll/min 2.18 ll/min 5.55 ll/min 7.19 ll/min
CLPL-TFV,a 0.09 ± 0.03 ll/min 1.64 ll/min 4.17 ll/min 5.39 ll/min
CLTFV-PL 3.69 ± 1.57 ll/min 67.2 ll/min 170.8 ll/min 221.1 ll/min
CLPL-CM,p 0.017 ± 0.007 ll/min 0.24 ll/min 0.81 ll/min 1.01 ll/min
CLPL-CM,a N.A. N.A. N.A. N.A.
CLCM-PL 4.37 ± 1.81 ll/min 62.4 ll/min 207.4 ll/min 258.4 ll/min
QECF 0.2 ll/min (Abbott, 2004;
Cserr et al., 1981)
10.5 ll/min (based on 0.11
ll/min/g brain (Cserr et al., 1981))
50% of QCSF (Kimelberg, 2004) (0.1
ml/min in 9 year old)
0.175 ml/min (Kimelberg, 2004)
QCSF 2.2 ll/min (Cserr, 1965) 63 ll/min (Bering, 1959) (8.798 * log(BW)  1.365)/60 ml/min
(Yasuda et al., 2002) (0.2 ml/min in
9 year old)
0.4 ml/min (Nilsson et al., 1992)
VPL 10.6 ml (Lee and Blaufox,
1985)
1112 ml (Visser et al., 1982) Age-dependent (Linderkamp et al., 1977)
(1600 ml for 9 year old)
2900 ml (Frank and Gray, 1953)
VPER,rapid 49.7% of bodyweight
(Davies and Morris, 1993)
64.1% of bodyweight (Davies and
Morris, 1993)
Age-dependent (ICRP, 2002) (36.1% of
bodyweight for 9 year old)
35.0% of bodyweight (ICRP, 2002)
VPER,slow 45.5% of bodyweight
(Davies and Morris, 1993)
26.2% of bodyweight (Davies and
Morris, 1993)
Age-dependent (ICRP, 2002) (48.0% of
bodyweight for 9 year old)
58.6% of bodyweight (ICRP, 2002)
VECF 290 ll (Cserr et al., 1981) 19 ml (based on 95.5 g brain)
(Bering, 1959)
270 ml (Thorne et al., 2004) (based on
1350 g brain) (Dekaban and Sadowsky,
1978)
280 ml (Thorne et al., 2004) (based
on
1400 g brain) (Dekaban and
Sadowsky, 1978)
VCSF,total 300 ll (Bass and Lundborg,
1973)
15.6 ml (Löfgren et al., 1973) 3 ml/kg (2–12 y) 1.75 ml/kh (>12 y)
(Troncin and Dadure, 2009) (90 ml
for 9 year old)
140 ml (Kimelberg, 2004)
VLV 50 ll (Condon et al., 1986;
Kohn et al., 1991)
3.8 ml (Vladic´ et al., 2009)
(24% of total CSF volume)
17% of total CSF volume
(Condon et al., 1986;
Kohn et al., 1991)
22.5 ml (Condon et al., 1986; Dickey
et al., 2000; Kohn et al., 1991)
VTFV 50 ll (Levinger, 1971) 1.3 ml (Vladic´ et al., 2009)
(8% of total CSF volume)
17% of total CSF volume
(Condon et al., 1986;
Kohn et al., 1991)
22.5 ml (Condon et al., 1986; Kohn
et al., 1991)
VCM 17 ll (Adam and Greenberg,
1978; Robertson, 1949)
0.9 ml (6% of total CSF volume
(human value))
6% of total CSF volume
(Adam and Greenberg, 1978;
Robertson, 1949)
7.5 ml (Adam and Greenberg, 1978;
Robertson, 1949)
VSAS 180 ll (Bass and Lundborg,
1973; Levinger, 1971)
9.0 ml (60% of total CSF volume
(human value))
60% of total CSF volume 90 ml (Pardridge, 2011)
gCLE 0.11 ± 0.02 0.11 0.11 0.11
ePL 0.18 ± 0.03 0.18 0.18 0.18
eST 0.07 ± 0.02 0.07 0.07 0.07
eLV 0.31 ± 0.09 0.31 0.31 0.31
eCM 0.25 ± 0.06 0.25 0.25 0.25
Parameter values in italic are derived from literature. Fu,p is the fraction unbound in plasma, CLE is the elimination clearance from plasma. For transfer clearances between
compartments (CLfrom comp-to comp), denotations of the compartments are: PL = plasma; PER,rapid = rapidly equilibrating peripheral tissues; PER,slow = slowly equilibrating
peripheral tissues; ECF = brainECF; LV = lateral ventricle; TFV = third and fourth ventricle; CM = cisterna magna; and SAS = subarachnoid space. V = physiological volume.
gi = inter-individual variability of parameter i; ej = residual error on concentrations in compartment j. The additional subscripts ‘p’ and ‘a’ denote passive and active transport,
respectively. N.A. implicates that the parameter is not available in the speciﬁc model.
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that were estimated based on our data (Table 3), there appears to
be a small underestimation of the elimination from plasma as well
as a small underestimation of the initial brainECF concentrations for
the control rats (Fig. 4A) (but both plasmau and brainECF data are in
general still within the range of 5–95% of the model prediction of
the data). However, for the group of rats with measurement of
plasma and ipsilateral brainECF concentrations at 11 days post-tu-
mor implantation, the concentration–time proﬁles in brainECF in
brain tumor were substantially higher than was the case for thehealthy situation (Fig. 4B). Presence and size of tumor were deter-
mined histologically after the end of the experiment. Simulations
indicated that these higher brainECF concentrations are most likely
caused by an increased plasma-to-brainECF clearance rate in brain
tumor conditions (results not shown).
3.5. Extrapolation to healthy dogs
We have also tried to predict the plasmau and CSF kinetics of
methotrexate in healthy dogs by systems-based scaling of our rat
Fig. 3. The visual predictive check of the ﬁnal SBPK model. The dots represent the individual data points and the gray area represents the 95% prediction conﬁdence interval.
The different boxes represent the plasmau, brainECF, CSFLV and CSFCM data.
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by Neuwelt et al. (1985). Plasma concentrations were ﬁrst cor-
rected for the level of protein binding, which was assumed to be
40% (Henderson et al., 1965). The rate of renal clearance was
assumed to equal the glomerular ﬁltration rate (80.2 ml/min
(Von Hendy-Willson and Pressler, 2011)). Systems-based scaling
of our data initially resulted in a 100-fold underestimation of dog
plasmau and CSFCM concentrations, whereas the CSFCM-to-plasmau
concentration ratio was predicted correctly. The underestimation
of the plasmau and CSFCM concentrations was primarily caused
by an overestimation of the plasma elimination clearance. As the
number of hepatocytes per gram liver in dogs is twice as much
compared to rats (Bayliss et al., 1999), the rate of hepatic clearance
was scaled to the liver weight and then multiplied by 2. With an
assumed liver weight of 720 g in the dog (Davies and Morris,
1993), the rate of hepatic clearance was estimated to be
1094 ml/min. However, in the rat, methotrexate is eliminated both
via the kidneys as well as the liver, whereas in dogs methotrexate
is eliminated primarily via the kidneys (Henderson et al., 1965).
This indicates that the estimation of the hepatic clearance rate in
dogs was much too high. For healthy dogs, with a hepatic clearance
being approximately 10% of the renal clearance (Henderson et al.,Fig. 4. Observed and SBPK model predicted methotrexate plasmau and brainECF concent
with ipsilateral brainECF measurement after 11 days (plasmau, n = 6; brainECF, n = 6) (D
represent animals in which no tumor was present on subsequent histological examinati
95% prediction conﬁdence interval. The different boxes represent the plasmau and brain1965), using the physiological and adapted PK parameters pre-
sented in Table 3, the prediction was much improved and resulted
in a slight underestimation of plasmau and CSFCM concentrations
(Fig. 5). Yet the CSFCM-to-plasmau concentration ratio was still pre-
dicted correctly.
3.6. Extrapolation to diseased human adults and children
The only available human brainECF concentration–time proﬁles
were derived from Blakeley et al. (2009), from 2 adult patients with
supratentorial glioma. Other data included human plasma and
CSFLV concentration–time proﬁles in adults with meningeal leuke-
mia or meningeal carcinomatosis (n = 21, Shapiro et al., 1975), pri-
mary tumor (n = 16, Glantz et al., 1998), or only plasma
concentration–time proﬁles in adults with small-cell lung carci-
noma (n = 9, Creaven et al., 1976), various neoplastic diseases
(n = 8, Bore et al., 1987) or rheumatoid arthritis (n = 56, Herman
et al., 1989; Stewart et al., 1990). Also included were plasma and
CSFCM concentration–time proﬁles from children with medullo-
blastoma or ependymoblastoma (n = 4, Chatelut et al., 1991), plas-
ma and CSFSAS concentration–time proﬁles from children with
non-Hodgkin’s lymphoma (n = 29, Vassal et al., 1990), or onlyrations in (A) control rats (plasmau, n = 5; brainECF, n = 6); (B) tumor implanted rats
e Lange et al., 1995). Note that the two lowest concentration–time proﬁles in (B)
ons. The dots represent the individual data points and the gray area represents the
ECF data.
Fig. 5. Observed and SBPK predicted methotrexate plasmau and CSFCM concentrations in (healthy) dogs (plasmau, n = 12; CSFCM, n = 4). The dots represent the average data
points as could be obtained from Neuwelt et al. (1985) and the gray area represents the 95% prediction conﬁdence interval. The different boxes represent the plasmau and
CSFCM data. The hepatic clearance in dogs was assumed to be 10% of the renal clearance for the ﬁnal SBPK predictions.
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phoblastic leukemia (n = 49, Aumente et al., 2006) or osteosarcoma
(n = 14, Colom et al., 2009). For constructing the adult and child
plasma, CSFLV, CSFCM and CSFSAS dataset, either the individual or
average datapoints from the different references were used, when
available. Otherwise, simulations were performed based on the PK
parameters presented in the different references.
All plasma concentrations were ﬁrst corrected for the level of
protein binding, which was assumed to be 32% for high dose meth-
otrexate (Skibin´ska et al., 1990). Systems-based scaling of our data
initially resulted in a 100-fold underestimation of human plasmau,
brainECF and CSF concentrations for both adults and children (re-
sults not shown). Again, the underestimation of the plasmau,
brainECF and CSF concentrations was primarily caused by an over-
estimation of the elimination clearance. For the systems-based
scaling of the elimination clearance of methotrexate it was as-
sumed that the rate of human renal clearance equals the glomeru-
lar ﬁltration rate (125 ml/min in adults (Davies and Morris, 1993)
and approximately 80 ml/min in 9 year-old children (the average
age of the available datasets)). As the number of hepatocytes per
gram liver is equal between rats and humans (Bayliss et al.,
1999), the rate of hepatic clearance is scaled to the liver weight.
With an assumed liver weight of 10 g in the rat (Davies and Morris,
1993), 780 g in 9 year old children and 1820 g in adults (ICRP,
2002), the rate of hepatic clearance is estimated to be 593 ml/
min and 1380 ml/min in 9 years old children and adults, respec-
tively. However, due to the extensive enterohepatic circulation of
methotrexate in humans, the hepatic elimination rate is effectively
reduced to the same level as the renal elimination rate (Hendel and
Brodthagen, 1984). So, when taking into account that the hepatic
clearance rate of methotrexate in humans is much lower than
the extrapolated value, i.e. equal to the renal clearance rate, the
predicted human plasmau concentrations are comparable to the
observed concentrations (Fig. 6). However, even though the human
plasmau concentrations can be predicted reasonably well with sys-
tems-based scaling of our rat data and adaption of the hepatic
clearance rate to those reported for human (Table 3), this approach
still results in an up to 10-fold underestimation of brainECF, CSFCM
and CSFLV concentrations in both children and adults, respectively.
Scaling of the blood-to-brain clearance values on the basis of the
total surface area of the BBB (150 cm2 in rats (Gjedde, 1981; Keepand Jones, 1990a); 200,000 cm2 in human adults (Pardridge, 2002))
and BCSFB (75 cm2 in rats (Keep and Jones, 1990b), 2000–
100,000 cm2 in human adults (Dohrmann, 1970)), rather than to
the tissue weight to the power 0.67, did not improve the predic-
tions (results not shown).
BrainECF and CSFLV concentrations in adults, as shown in Fig. 6a,
were not obtained in parallel, but from different subjects, also hav-
ing other diseases. However, these are the only data available to
make a comparison between these two unbound brain concentra-
tions. Both brainECF and CSFLV concentrations are higher than pre-
dicted by the SBPK model, while the observed brainECF-to-CSFLV
concentration ratio is in accordance with the predicted
brainECF-to-CSFLV concentration ratio. It therefore seems that the
plasma-to-brain concentration ratio is increased by disease condi-
tions. Speciﬁcally, simulations indicated that the brainECF-to-CSF
concentration ratio in diseased adults and children is equal to
2.6, which is approximately 3-fold lower than the brainECF-to-CSF
concentration ratio observed in healthy rats, being most likely
caused by an overestimation of the brainECF-to-plasma clearance
rate. It indicates that under disease conditions there is a decreased
active efﬂux from the brainECF to plasma (results not shown). On
the other hand, simulations indicated that the underestimation
of CSF concentrations in disease conditions is most likely caused
by an overestimation of the CSF ﬂow. This is in line with the obser-
vation that several adult patients had an obstruction to normal CSF
ﬂow (Glantz et al., 1998) (results not shown).
Overall, the observed and SBPK model predicted plasmau,
brainECF, CSFLV, CSFCM and CSFSAS concentration–time proﬁles in
healthy and diseased rats, dogs, children and adults are summa-
rized in Fig. 7.
4. Discussion
By using the parallel microdialysis approach (Westerhout et al.,
2012), we have previously shown that, even for acetaminophen, a
model compound for passive transport into, within and out of the
brain, differences exist between CSF and brainECF kinetics (West-
erhout et al., 2012). Furthermore, we have also shown that for
quinidine, a model compound for P-gp mediated transport, differ-
ences exist between CSF and brainECF kinetics, which are very
much dependent of P-gp functionality (Westerhout et al., 2013).
Fig. 6. (A) Observed and predicted methotrexate plasma, brainECF and CSFLV concentrations in (diseased) adults; (B) observed and predicted methotrexate plasma, CSFLV and
CSFSAS concentrations in (diseased) children. Plasma data from adults and children were collected from different studies (see text and Table 4). Adult brainECF data were
obtained from 2 patients with supratentorial glioma (Blakeley et al., 2009). Adult CSFLV data were obtained from 21 patients with meningeal leukemia or meningeal
carcinomatosis (Shapiro et al., 1975) or 16 patients with primary tumor (Glantz et al., 1998). Child CSFLV data were obtained from 4 patients (serial sampling) with
medulloblastoma or ependymoblastoma (Chatelut et al., 1991). Child CSFSAS data were obtained from 29 patients (single sample) with non-Hodgkin’s lymphoma (Vassal et al.,
1990). The dots represent the individual data points and the gray area represents the 95% prediction conﬁdence interval. The different boxes represent the plasmau, brainECF,
CSFLV and CSFSAS data. The hepatic clearance in humans was assumed to be equal to the renal clearance for the ﬁnal SBPK predictions.
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porters that are all located at the BBB and BCSFB, including RFC1
(Hinken et al., 2011), BCRP (Breedveld et al., 2007), MRP 2, 3 and
4 (Vlaming et al., 2011), OAT 1 and 3 (Takeda et al., 2002), and
OATP A (Badagnani et al., 2006) and OATP B (van de Steeg et al.,
2009), this could have major implications for the predictability of
brainECF methotrexate concentrations on the basis of CSF metho-
trexate concentrations.
In this study, the parallel microdialysis approach was used to
investigate methotrexate distribution to and within the brain,
and the speciﬁc contribution of the various transporters on the
brain distribution of methotrexate. Probenecid was co-adminis-
tered as inhibitor of Mrps (Bakos et al., 2000), Oats (Sugiyama
et al., 2001) and Oatps (Kis et al., 2013). Probenecid is known to in-
hibit Mrps, Oats and Oatps with a half-maximum inhibition con-
stant (IC50) of approximately 50–300 lg/ml (Bakos et al., 2000),
5–20 lg/ml (Sugiyama et al., 2001) and 1.1 lg/ml (Kis et al.,Fig. 7. Observed and SBPK predicted methotrexate plasmau, brainECF, CSFLV, CSFCM and CS
Lange et al., 1995); (C) diseased rats (De Lange et al., 1995); (D) healthy dogs (Neuwelt et
references). The dots represent the individual data points and the gray area represents
brainECF, CSFLV, CSFCM and CSFSAS data. For healthy dogs and diseased humans the hepatic
Note: please mind the differences in the time-scales presented here.2013), respectively. Previous work by Emanuelsson and Paalzow
(1988) has indicated that a 150 mg/kg dose of probenecid results
in plasma concentrations over 10-fold higher than the IC50 value
up to 3 h after administration. Therefore, it is plausible to assume
that the dose of probenecid is sufﬁcient to fully inhibit Mrps, Oats
and Oatps throughout the entire experimental period.
We investigated the direct relationships between brain ST
methotrexate concentrations and those in different CSF locations,
and unbound plasma methotrexate concentrations in the rat. Pre-
vious work from our group has indicated that the methotrexate
brainECF-to-plasmatotal AUC ratio is approximately 5% in healthy
rats (De Lange et al., 1995). Similar ﬁndings have been reported
for the CSF-to-plasmatotal AUC ratio (Wang et al., 2003). When tak-
ing into consideration the level of plasma protein binding and the
differences in sampling methods, our current results are in line
with these ﬁndings. Combined results of de Lange et al. (1995),
and Wang et al. (2003) would indicate that brainECF exposureFSAS concentration–time proﬁles in (A) healthy rats (this study); (B) healthy rats (De
al., 1985); (E) diseased children (multiple references); (F) diseased adults (multiple
the 95% prediction conﬁdence interval. The different boxes represent the plasmau,
clearance was adapted as described in chapter 3.5 and in this chapter, respectively.
J. Westerhout et al. / European Journal of Pharmaceutical Sciences 57 (2014) 11–24 21and CSF exposure are more-or-less similar. However, in the current
study, measuring parallelly at both sites within individual rats, we
have found that brainECF exposure of methotrexate is signiﬁcantly
higher than CSF exposure. Inhibition of Mrps, Oats and Oatps by
probenecid resulted in a signiﬁcant increase in brainECF concentra-
tions only. CSF concentrations seemed to be affected, but not to a
signiﬁcant extent, due to variability (as expected for a drug like
methotrexate (Spector and Johanson, 2010)). Interestingly, the
brainECF-to-CSF concentration ratio was not signiﬁcantly inﬂu-
enced by co-administration of probenecid. This is in contrast with
the P-gp substrate quinidine, for which the relation between
brainECF and CSF concentrations was dependent on P-gp function-
ality (Westerhout et al., 2013).
Advanced mathematical modeling was applied, using the same
structural SBPK model that was previously used for acetaminophen
(Westerhout et al., 2012) and quinidine (Westerhout et al., 2013).
For methotrexate the model parameters were estimated using the
experimental data obtained in this study. The resulting SBPKmodel
was further used to predict data obtained in other conditions and
species, taking into account changes in physiological parameters.
First, the SBPK model was used to investigate the impact of dis-
ease-status on the PK of methotrexate in plasmau and brainECF of
brain tumor-bearing rats, compared to healthy control rats as
presented by De Lange et al. (1995). Fig. 4A shows that the model
prediction of plasma and brainECF concentrations is reasonably
good. Then, Fig. 4B shows the SBPK prediction for healthy rat con-
ditions, for rats in which a tumor (rhabdomyosarcoma) had been
implanted in the brain (De Lange et al., 1995). It shows that tu-
mor-bearing rats have speciﬁcally increased early methotrexate
brainECF concentrations.
Then, systems-based scaling of our healthy rat data to healthy
dogs initially resulted in a 10–100-fold underestimation of plasmau
and CSF concentrations. However, by taking into account that he-
patic elimination of methotrexate in dogs is only a fraction of the
renal clearance (Henderson et al., 1965), the prediction of plasmau
and CSF concentrations is much improved. The CSFCM-to-plasmauTable 4
Different variables in disease states and experimental conditions of the available datasets
Reference Subjects Disease state Dose (i.v.)
This manuscript Rats (225–275 g;
n = 32)
Healthy 40 and 80 m
De Lange et al. (1995) Rats (160–200 g;
n = 12)
Brain tumor (implanted
rhabdomyo-sarcoma)
75 mg/kg (b
Neuwelt et al. (1985) Dogs (20–25 kg;
n = 4)
Healthy 4 mg/kg (bo
Aumente et al. (2006) Children (0.5–17
y; n = 49)
Acute lymphoblastic
leukemia
3 g/m2 (4 h
therapy (>2
Blakeley et al. (2009) Human adults
(>18 y; n = 2)
Recurrent high grade gliomas 12 g/m2 (4
Bore et al. (1987) Human adults
(17–67 y; n = 8)
Sarcoma, carcinoma, lung
metastasis
50 mg/m2 (
Chatelut et al. (1991) Children (2–17
y; n = 4)
Medulloblastoma or
ependymo-blastoma
8 g/m2 (4 h
(i.v. hydrati
Colom et al. (2009) Children (n = 14) Osteosarcoma 12 g/m2 (4
methotrexa
Creaven et al. (1976) Human adults
(n = 9)
Small-cell lung carcinoma 15 mg/m2 (
Glantz et al. (1998) Human adults
(>18 y; n = 16)
Histologically diagnosed
primary tumor
8 g/m2 (4 h
methotrexa
Herman et al. (1989) Human adults
(16–80 y; n = 41)
Rheumatoid arthritis 10 mg/m2 (
Shapiro et al. (1975) Human adults
(18–63 y; n = 21)
Leukemia and carcinoma 50 mg (bolu
Stewart et al. (1990) Human adults
(30–78 y; n = 15)
Rheutmatoid arthritis 15 mg (5 m
3 days befo
Vassal et al. (1990) Children (3–15 y;
n = 29)
NonHodgkin’s lymphoma 3 g/m2 (3 h
(i.v. hydraticoncentration ratio was predicted correctly. This implicates that
the SBPK model of brain distribution developed for the healthy
rat seemed to apply correctly for healthy dogs, provided that the
hepatic clearance is corrected. Our ultimate aim is to predict
human brain distribution, in health and disease. The human meth-
otrexate data available in literature, however, were all obtained
under disease conditions, hampering a direct evaluation of the
SBPK model in predicting human brain distribution of methotrex-
ate. But, with the assumption that the SBPK model could appropri-
ately predict methotrexate brain distribution in humans, the SBPK
model can be used to identify changes brought about by disease
conditions. To that end, it should be realized that not only brain
diseases can inﬂuence brain distribution, as was demonstrated by
changes in BBB transport of the permeability marker ﬂuorescein
for rats with peripheral inﬂammation upon chronic exposure to
rotenone (Ravenstijn et al., 2008).
Extrapolation of our healthy rat data to humans with different
disease states initially resulted in a 100-fold underestimation of
plasmau, brainECF and CSF concentrations. However, by taking into
account that methotrexate undergoes extensive enterohepatic cir-
culation in humans (Hendel and Brodthagen, 1984), the prediction
of plasmau concentrations is much improved. Yet, under the given
disease conditions, the brainECF and CSF concentrations are up to
10-fold higher than predicted for healthy conditions. Using the
SBPK model, simulations indicate a possible decreased active efﬂux
from the brainECF as well as a lower CSF ﬂow under disease condi-
tions. Actually, Glantz et al. (1998) reported that several patients
had abnormal (low) CSF ﬂow. It should be realized however, that
the human data available from literature reﬂect methotrexate dis-
position in body and brain in a variety of diseases that probably do
not affect body processes in the same manner. So, more speciﬁc
data are needed to identify speciﬁc disease related processes that
inﬂuence brain distribution of methotrexate, and could lead to
more personalized treatment.
Alternatively, or in addition, differences between SBPK
predicted human healthy and the observed human diseasein rats, dogs, children and adults.
BrainECF or CSF (sampling
method)
Analysis
g/kg (10 min) BrainECF, CSFLV and CSFCM
(microdialysis)
LC/MS/MS
olus) BrainECF (microdialysis) HPLC
lus) + Evans blue CSFCM (Cisterna magna
sampling)
Radioimmuno-assay
) + remission-induction
4 h after methotrexate)
N.A. Fluorescence polarization
immunoassay
h) + sodium bicarbonate BrainECF (intratumoral
microdialysis)
LC/MS
bolus) (no co-medication) N.A. Radioimmuno-assay
) + sodium bicarbonate
on)
CSFLV (ventriculo-
peritoneal derivation)
Enzymatic assay
h) + leucovorin (24 h after
te)
N.A. Fluorescence polarization
immunoassay
bolus) (no co-medication) N.A. [3H]Metho-trexate
) + leucovorin (24 h after
te)
CSFLV (ventricular
reservoirs)
Fluorescence polarization
immunoassay
bolus) (no co-medication) N.A. Radiochemical-ligand
binding assay
s) (no co-medication) CSFLV (Ommaya reservoir) Microbiologic disk assay
in) (received naproxen
re)
N.A. Radioenzymatic assay
) + sodium bicarbonate
on)
CSFSAS (lumbar puncture) Fluorescence polarization
immunoassay
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tion, sampling methods analysis methods (Table 4).
Possible species differences in the abundance levels and activi-
ties of the different active transport proteins at the BBB and BCSFB,
under healthy and diseased conditions, probably also play an
important role. It has been previously shown that the genetic var-
iability in transporters in humans leads to an altered sensitivity to
methotrexate and thus inﬂuences the toxicity and/or efﬁcacy of
methotrexate treatment (Kotnik et al., 2011). This indicates that
additional information on the species differences in abundance
levels and activities of the different active transport proteins and
drug-metabolizing enzymes at the BBB and BCSFB, as well as at
the liver and kidney, under healthy or diseased conditions, is
essential for extrapolation purposes.
5. Conclusion
It is concluded that in parallel obtained data on unbound
brainECF, CSF and plasma concentrations, under dynamic condi-
tions, combined with advanced mathematical modeling is a most
valid approach to develop SBPK models that allow to reveal the
mechanisms underlying the relationship between brainECF and
CSF concentrations. In contrast to the P-gp substrate quinidine
and P-gp mediated active transport, for methotrexate we have
found that inhibition of Mrp/Oat/Oatp-mediated active transport
processes does not signiﬁcantly inﬂuence the relationship between
brainECF and CSF concentrations.
Our results suggest that the extrapolation of our healthy rat
data to healthy dogs works reasonably well, provided that informa-
tion on the different elimination routes, or the lack thereof, is
included in the systems-based scaling approach. For the correct
prediction of plasmau, brainECF or CSF concentrations in diseased
humans, additional information is needed on speciﬁc disease states
in order to identify which processes are inﬂuenced by the disease
condition to improve personalized treatment, in which the SBPK
model is anticipated to be a useful tool.
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Appendix A
A.1. Differential equations
The mass balance equations describing the ﬁnal SBPK model
were expressed as follows:
Plasma:
dAPL;u
dt
¼ dose kPL-PER;rapid  APL;u þ kPER;rapid-PL  APER;rapid  kPL-PER;slow
 APL;u þ kPER;slow-PL  APER;slow  kPL-ECF  APL;u þ kECF-PL  AECF
 kPL-LV  APL;u þ kLV-PL  ALV  kPL-TFV  APL;u þ kTFV-PL  ATFV
 kPL-CM  APL;u þ kCM-PL  ACM þ QCSFVSAS
 
 ASAS  kE  APL;u
CPL;u ¼ APL;uVPL
Periphery:
dAPER;rapid
dt
¼ kPL-PER;rapid  APL;u  kPER;rapid-PL  APER;rapidCPER;rapid ¼ APER;rapidVPER;rapid
dAPER;slow
dt
¼ kPL-PER;slow  APL;u  kPER;slow-PL  APER;slow
CPER;slow ¼ APER;slowVPER;slow
BrainECF:
dAECF
dt
¼ kPL-ECF  APL;u  kECF-PL  AECF  QECFVECF
 
 AECF
CECF ¼ AECFVECF
CSFLV:
dALV
dt
¼ kPL-LV  APL;u  kLV-PL  ALV þ QECFVECF
 
 AECF  QCSFVLV
 
 ALV
CLV ¼ ALVVLV
CSFTFV:
dATFV
dt
¼ kPL-TFV  APL;u  kTFV-PL  ATFV þ QCSFVLV
 
 ALV  QCSFVTFV
 
 ATFV
CTFV ¼ ATFVVTFV
CSFCM:
dACM
dt
¼ kPL-CM  APL;u  kCM-PL  ACM þ QCSFVTFV
 
 ATFV  QCSFVCM
 
 ACM
CCM ¼ ACMVCM
CSFSAS:
dASAS
dt
¼ QCSF
VCM
 
 ACM  QCSFVSAS
 
 ASAS
CSAS ¼ ASASVSAS
where:
kE ¼ ðCLE;p þ CLE;aÞ=VPL
kPL-PER;rapid ¼ CLPL-PER;rapid=VPL
kPER;rapid-PL ¼ CLPL-PER;rapid=VPER;rapid
kPL-PER;slow ¼ CLPL-PER;slow=VPL
kPER;slow-PL ¼ CLPL-PER;slow=VPER;slow
kPL-ECF ¼ ðCLPL-ECF;p  CLPL-ECF;aÞ=VPL
kECF-PL ¼ ðCLECF-PL;p þ CLECF-PL;aÞ=VECF
kPL-LV ¼ ðCLPL-LV;p  CLPL-LV;aÞ=VPL
kLV-PL ¼ ðCLLV-PL;p þ CLLV-PL;aÞ=VLV
kPL-TFV ¼ ðCLPL-TFV;p  CLPL-TFV;aÞ=VPL
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